Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 10/20 | 0.56 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.37 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.37 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.37 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.34 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.34 |
| ▸ | CD44 | P16070 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.33 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.33 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.33 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.33 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4397849 | 0.82 | PNMT (0.61) | PNMTTPSAB1TPSD1TPSG1ITGB3 | |
| SCHEMBL27932728 | 0.77 | PNMT (0.54) | PNMTTPSAB1TPSD1TPSG1ITGB3 | |
| SCHEMBL1444085 | 0.76 | PNMT (0.61) | PNMTTPSAB1TPSD1TPSG1ITGB3 | |
| SCHEMBL7527801 | 0.74 | PNMT (0.51) | PNMTTPSAB1TPSD1TPSG1ITGB3 | |
| Hydrochloric Acid SCHEMBL1443367 | 0.74 | PNMT (0.60) | PNMTTPSAB1TPSD1TPSG1ITGB3 | |
| SCHEMBL3053106 | 0.73 | PNMT (0.50) | PNMTTPSAB1TPSD1TPSG1ITGB3 | |
| SCHEMBL21236155 | 0.73 | PNMT (0.63) | PNMTTPSAB1TPSD1TPSG1CD44 | |
| SCHEMBL13287392 | 0.72 | PNMT (0.45) | PNMTTPSAB1TPSD1TPSG1ITGB3 | |
| SCHEMBL9471965 | 0.72 | PNMT (0.54) | PNMTTPSAB1TPSD1TPSG1ITGB3 | |
| SCHEMBL15071934 | 0.72 | PNMT (0.54) | PNMTTPSAB1TPSD1TPSG1ITGB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0785205-B1 | 2-SILYLOXYTETRAHYDROTHIENOPYRIDINE, SALT THEREOF, AND PROCESS FOR PRODUCING THE SAME | UBE INDUSTRIES (JP) | 2002-04-17 | — | — | EP | claimed |
| US-5874581-A | CHEMICAL INTERMEDIATE OF AN ANTIPLATELET MEDICINE AND AN ELASTASE INHIBITOR; REACTING A HALOSILANE AND A 2-OXO-4,5,6,7 -TETRAHYDROTHIENO(3,2-C)PYRIDINE IN THE PRESENCE OF A TERTIARY AMINE | UBE INDUSTRIES, LTD. (JP) | 1999-02-23 | — | — | US | claimed |
| EP-0785205-A1 | 2-SILYLOXYTETRAHYDROTHIENOPYRIDINE, SALT THEREOF, AND PROCESS FOR PRODUCING THE SAME | UBE INDUSTRIES, LTD. (JP) | 1997-07-23 | — | — | EP | claimed |
| CN-103254211-A | Method for preparing vicagrel and derivatives thereof | JIANGSU VCARE PHARMATECH CO LTD | 2013-08-21 | — | — | CN | disclosed |
| US-20110003847-A1 | Prasugrel Salts with Improved Properties | HELM AG (DE) | 2011-01-06 | — | — | US | disclosed |
| EP-0785205-B1 | 2-SILYLOXYTETRAHYDROTHIENOPYRIDINE, SALT THEREOF, AND PROCESS FOR PRODUCING THE SAME | UBE INDUSTRIES (JP) | 2002-04-17 | — | — | EP | disclosed |
| EP-0785205-B1 | 2-SILYLOXYTETRAHYDROTHIENOPYRIDINE, SALT THEREOF, AND PROCESS FOR PRODUCING THE SAME | UBE INDUSTRIES (JP) | 2002-04-17 | — | — | EP | disclosed |
| EP-0785205-A4 | 2-SILYLOXYTETRAHYDROTHIENOPYRIDINE, SALT THEREOF, AND PROCESS FOR PRODUCING THE SAME | UBE INDUSTRIES (JP) | 1999-12-15 | — | — | EP | disclosed |
| US-5874581-A | CHEMICAL INTERMEDIATE OF AN ANTIPLATELET MEDICINE AND AN ELASTASE INHIBITOR; REACTING A HALOSILANE AND A 2-OXO-4,5,6,7 -TETRAHYDROTHIENO(3,2-C)PYRIDINE IN THE PRESENCE OF A TERTIARY AMINE | UBE INDUSTRIES, LTD. (JP) | 1999-02-23 | — | — | US | disclosed |
| US-5874581-A | CHEMICAL INTERMEDIATE OF AN ANTIPLATELET MEDICINE AND AN ELASTASE INHIBITOR; REACTING A HALOSILANE AND A 2-OXO-4,5,6,7 -TETRAHYDROTHIENO(3,2-C)PYRIDINE IN THE PRESENCE OF A TERTIARY AMINE | UBE INDUSTRIES, LTD. (JP) | 1999-02-23 | — | — | US | disclosed |
| EP-0785205-A1 | 2-SILYLOXYTETRAHYDROTHIENOPYRIDINE, SALT THEREOF, AND PROCESS FOR PRODUCING THE SAME | UBE INDUSTRIES, LTD. (JP) | 1997-07-23 | — | — | EP | disclosed |
| EP-0785205-A1 | 2-SILYLOXYTETRAHYDROTHIENOPYRIDINE, SALT THEREOF, AND PROCESS FOR PRODUCING THE SAME | UBE INDUSTRIES, LTD. (JP) | 1997-07-23 | — | — | EP | disclosed |
| WO-1996011203-A1 | 2-SILYLOXYTETRAHYDROTHIENOPYRIDINE, SALT THEREOF, AND PROCESS FOR PRODUCING THE SAME | UBE INDUSTRIES, LTD. (JP) | 1996-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003847-A1 | Prasugrel Salts with Improved Properties | P2RY6, PF4, PFKP | PNMT 4786/4885TPSAB1 1194/4885TPSD1 2482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.